Investing.com - Merck&Co (NYSE: MRK) reported fourth quarter EPS of $1.62, $0.09 better than the analyst estimate of $1.53. Revenue for the quarter came in at $13.8B versus the consensus estimate of $13.65B.
Guidance
Merck&Co sees FY 2023 EPS of $6.80-$6.95 versus the analyst consensus of $7.36.
Merck&Co sees FY 2023 revenue of $57.20B-$58.70B versus the analyst consensus of $58.07B.
Merck&Co's stock price closed at $106.98. It is up 7.84% in the last 3 months and up 35.40% in the last 12 months.
Merck&Co saw 9 positive EPS revisions and 5 negative EPS revisions in the last 90 days. See Merck&Co's stock price’s past reactions to earnings here.
According to InvestingPro, Merck&Co's Financial Health score is "great performance".
Check out Merck&Co's recent earnings performance, and Merck&Co's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar